Browsing Tag
biotechnology
76 posts
Why oncology clinicians are watching EOM613’s effect on muscle loss, appetite, and chemotherapy readiness
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
How VERVE-102 could accelerate the transition from chronic lipid therapy to genomic medicine
Could VERVE-102 shift cholesterol treatment from chronic therapy to one-time gene editing? Explore Eli Lilly and Company’s genomic medicine strategy.
How the cholestatic liver disease market is creating new opportunities for NTCP-targeting therapies
Assembly Biosciences is expanding ABI-6250 into PBC and PSC. Find out why NTCP-targeting therapies are gaining momentum in hepatology.
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Can in vivo CAR T therapies expand access beyond specialized treatment centers
Explore how CPTx’s in vivo CAR T strategy could lower costs, simplify delivery, and expand access beyond specialized cancer treatment centers.
Why BIOX-101 might succeed where decades of stroke research have struggled
Can BIOX-101 reshape stroke treatment timelines? Discover how Bioxodes SA’s strategy could accelerate approvals and change neurovascular care.
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Why industry observers are watching Tenvie Therapeutics’ TNV262 biomarker readout in 2026
Tenvie Therapeutics’ TNV262 readout in 2026 could reshape obesity and cardiometabolic drug development. Read why markets are watching closely.
Can Ocugen, Inc. disrupt chronic eye injections with a single gene therapy procedure? (NASDAQ: OCGN)
Ocugen, Inc. reports Phase 2 gene therapy results that could reshape retinal treatment economics. Discover what this means for investors and competitors.
Aelis Farma’s AEF0217 enters critical Phase 2B trial—can it become the first drug for Down syndrome cognition?
Aelis Farma launches Phase 2B trial for AEF0217 in Down syndrome—could this CB1-targeting drug finally deliver a breakthrough? Read more.